Satin Creditcare Network reported a consolidated net profit of Rs. 201 crore for FY19, registering a growth of 169 per cent YoY as against Rs. 75 crore in FY18 on a consolidated basis. The company reported revenues of Rs. 1,448 crore in FY19, up by 40 per cent YoY.

KEC International reported its results for the quarter ended March 31, 2019 on Wednesday after market hours. The company's consolidated revenue for Q4FY19 came in at Rs. 3,841.17 crore as against Rs. 3,662.37 crore in the corresponding quarter last year, registering 4.9 per cent yoy increase.

The stocks that are likely to witness significant movement on the bourses on May 9 are Lupin, Dilip Buildcon, Voltas, Eros International and UPL.

Market on Wednesday opened in the green but soon after the pre-opening session slipped in the red zone. Market trade around the 38,000 level for the most part of the first half of the day and then lost more ground in the afternoon session to close down by 487 points or 1.27 per cent. The biggest draggers were Tata Motors and Reliance.

The latest investors for the debt-ridden airline were a British airline, a non-resident Indian and investment firms Adi Partners, Future Trend Capital and Radcliffe Capital.

NBCC (India) has secured a total business of Rs. 361.91 crore in the month of April 2019. Earlier, the company had secured a total business of Rs. 3,031.70 crore in March 2019.

Indoco Remedies announced that it received approval from the UK-MHRA (Medicines and Healthcare Products Regulatory Agency) for its new solid dosages manufacturing facility in Baddi, Himachal Pradesh (Baddi III unit). The inspection was held from October 16 to 18, 2018.

We have found some mid-cap stocks that outperformed and underperformed in the month of April as compared to the mid-cap index. Read on to find out more....

Gujarat-based pipes and tubes manufacturer, Ratnamani Metals & Tubes Limited informed in the exchange through a filing that the company has secured a new order for CS coated pipes.

Natco Pharma’s marketing partner Alvogen has received final approval of Abbreviated New Drug Application (ANDA) from USFDA for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg.